Clinical Trial Update: Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (Prevnar 13) in HIV-infected individuals aged 6 years and old…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Pneumococcal Infection

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: HIV Infections, Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-11-17